Skip to main content

Management of Ulcerative Colitis in the Elderly

Abstract

The incidence rate of ulcerative colitis (UC) in older patients is rising. Diagnosis of UC may be difficult in older patients as several common gastrointestinal disorders can mimic UC in these patients. Compared with younger adults, left-sided colitis is more common in older-onset UC, while rectal bleeding, abdominal pain, and extraintestinal manifestations are less common. The disease course of older-onset UC may be similar to that of adult-onset UC. The management of UC in older patients includes medical and surgical options. A majority of older UC patients are treated with 5-aminosalicylates. The underuse of immunosuppressants or biologics may lead to poor disease control, higher use of corticosteroids, and worse clinical outcomes in older UC patients. Serious infections and malignancy are the most concerning complications of immune-modifying agents or biologics in the elderly. Timely surgical referral of older UC patients with poor disease control is of utmost importance as elective colectomy may be associated with improved survival in these patients.

This is a preview of subscription content, access via your institution.

References

  1. Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted county, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut. 2000;46(3):336–43.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted county, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13(3):254–61.

    Article  PubMed  Google Scholar 

  3. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.

    Article  PubMed  Google Scholar 

  4. Sturm A, Maaser C, Mendall M, et al. European Crohn’s and Colitis Organisation topical review on IBD in the elderly. J Crohns Colitis. 2017;11(3):263–73.

    PubMed  Google Scholar 

  5. Pardi DS, Loftus EV Jr, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update. Drugs Aging. 2002;19(5):355–63.

    Article  CAS  PubMed  Google Scholar 

  6. del Val JH. Old-age inflammatory bowel disease onset: a different problem? World J Gastroenterol. 2011;17(22):2734–9.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Katz S, Surawicz C, Pardi DS. Management of the elderly patients with inflammatory bowel disease: practical considerations. Inflamm Bowel Dis. 2013;19(10):2257–72.

    Article  PubMed  Google Scholar 

  8. Jeuring SF, van den Heuvel TR, Zeegers MP, et al. Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age-an increasing distinct entity? Inflamm Bowel Dis. 2016;22(6):1425–34.

    Article  PubMed  Google Scholar 

  9. Fries W, Viola A, Manetti N, et al. Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study”. Dig Liver Dis. 2017;49(1):17–23.

    Article  PubMed  Google Scholar 

  10. Hou JK, Feagins LA, Waljee AK. Characteristics and behavior of elderly-onset inflammatory bowel disease: a multi-center US study. Inflamm Bowel Dis. 2016;22(9):2200–5.

    Article  PubMed  Google Scholar 

  11. Nguyen GC, Bernstein CN, Benchimol EI. Risk of surgery and mortality in elderly-onset inflammatory bowel disease: a population-based cohort study. Inflamm Bowel Dis. 2017;23(2):218–23.

    Article  PubMed  Google Scholar 

  12. Lin WC, Tung CC, Lin HH, et al. Elderly adults with late-onset ulcerative colitis tend to have atypical, milder initial clinical presentations but higher surgical rates and mortality: a Taiwan society of inflammatory bowel disease study. J Am Geriatr Soc. 2016;64(10):e95–7.

    Article  PubMed  Google Scholar 

  13. Shi HY, Chan FK, Leung WK, et al. Natural history of elderly-onset ulcerative colitis: results from a territory-wide inflammatory bowel disease registry. J Crohns Colitis. 2016;10(2):176–85.

    Article  PubMed  Google Scholar 

  14. Song EM, Lee HS, Park SH, et al. Clinical characteristics and long-term prognosis of elderly onset ulcerative colitis. J Gastroenterol Hepatol. 2018;33(1):172–9.

    Article  PubMed  Google Scholar 

  15. Duricova D, Pariente B, Sarter H, et al. Impact of age at diagnosis on natural history of patients with elderly-onset ulcerative colitis: a French population-based study. Dig Liver Dis. 2018;50(9):903–9.

    Article  PubMed  Google Scholar 

  16. Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63(3):423–32.

    Article  PubMed  Google Scholar 

  17. Everhov AH, Halfvarson J, Myrelid P, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. Gastroenterology. 2018;154(3):518–28.

    Article  PubMed  Google Scholar 

  18. Lakatos PL, David G, Pandur T, et al. IBD in the elderly population: Results from a population-based study in Western Hungary, 1977–2008. J Crohns Colitis. 2011;5(1):5–13.

    Article  PubMed  Google Scholar 

  19. Manosa M, Calafat M, de Francisco R, et al. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. Aliment Pharmacol Ther. 2018;47(5):605–14.

    Article  CAS  PubMed  Google Scholar 

  20. Ananthakrishnan AN, Shi HY, Tang W, et al. Systematic review and meta-analysis: Phenotype and clinical outcomes of older-onset inflammatory bowel disease. J Crohns Colitis. 2016;10(10):1224–36.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther. 2014;39(5):459–77.

    Article  CAS  PubMed  Google Scholar 

  22. Kim M, Katz S, Green J. Drug management in the elderly IBD patient. Curr Treat Options Gastroenterol. 2015;13(1):90–104.

    Article  PubMed  Google Scholar 

  23. Ananthakrishnan AN, Binion DG. Treatment of ulcerative colitis in the elderly. Dig Dis. 2009;27(3):327–34.

    Article  PubMed  Google Scholar 

  24. Komoto S, Higashiyama M, Watanabe C, et al. Clinical differences between elderly-onset ulcerative colitis and non-elderly-onset ulcerative colitis: a nationwide survey data in Japan. J Gastroenterol Hepatol. 2018;33(11):1839–43.

    Article  PubMed  Google Scholar 

  25. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76.

    Article  CAS  PubMed  Google Scholar 

  26. Matsumoto S, Miyatani H, Yoshida Y. Ulcerative colitis: comparison between elderly and young adult patients and between elderly patients with late-onset and long-standing disease. Dig Dis Sci. 2013;58(5):1306–12.

    Article  PubMed  Google Scholar 

  27. Parian A, Ha CY. Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(6):1392–400.

    PubMed  PubMed Central  Google Scholar 

  28. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):30–5.

    Article  CAS  PubMed  Google Scholar 

  29. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929–36.

    Article  PubMed  Google Scholar 

  30. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143(2):390–9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Khan N, Abbas AM, Lichtenstein GR, Loftus EV Jr, Bazzano LA. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145(5):1007–15.

    Article  CAS  PubMed  Google Scholar 

  32. Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg. 2010;210(6):901–8.

    Article  PubMed  Google Scholar 

  33. McNallan SM, Singh M, Chamberlain AM, et al. Frailty and healthcare utilization among patients with heart failure in the community. JACC Heart Fail. 2013;1(2):135–41.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Huguet JM, Iborra M, Bosca-Watts MM, et al. Inflammatory bowel disease in patients over the age of 70 y. does the disease duration influence its behavior? Scand J Gastroenterol. 2018;2018:1–6.

    Google Scholar 

  35. Whitehead WE, Borrud L, Goode PS, et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology. 2009;137(2):pp. 512–7, 517.

    Article  Google Scholar 

  36. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(5):577–85.

    Article  CAS  PubMed  Google Scholar 

  37. Gisbert JP, Gonzalez-Lama Y, Mate J. 5-aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007;13(5):629–38.

    Article  PubMed  Google Scholar 

  38. Muller AF, Stevens PE, McIntyre AS, Ellison H, Logan RF. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther. 2005;21(10):1217–24.

    Article  CAS  PubMed  Google Scholar 

  39. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121(9):676–83.

    Article  CAS  PubMed  Google Scholar 

  40. Stallmach A, Hagel S, Gharbi A, et al. Medical and surgical therapy of inflammatory bowel disease in the elderly—prospects and complications. J Crohns Colitis. 2011;5(3):177–88.

    Article  PubMed  Google Scholar 

  41. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001;49(5):656–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):661–73.

    Article  CAS  PubMed  Google Scholar 

  43. Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med. 2012;4(6):1051–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014;20(1):21–35.

    Article  PubMed  Google Scholar 

  45. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105(3):501–23.

    Article  PubMed  Google Scholar 

  46. Khan N, Abbas AM, Almukhtar RM, Khan A. Prevalence and predictors of low bone mineral density in males with ulcerative colitis. J Clin Endocrinol Metab. 2013;98(6):2368–75.

    Article  CAS  PubMed  Google Scholar 

  47. Brassard P, Bitton A, Suissa A, Sinyavskaya L, Patenaude V, Suissa S. Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol. 2014;109(11):1795–802.

    Article  CAS  PubMed  Google Scholar 

  48. Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008;103(6):1428–35.

    Article  CAS  PubMed  Google Scholar 

  49. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W, American Gastroenterological Association. American gastroenterological association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130(3):940–87.

    Article  CAS  PubMed  Google Scholar 

  50. Benchimol EI, Cook SF, Erichsen R, et al. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J Crohns Colitis. 2013;7(11):878–89.

    Article  PubMed  Google Scholar 

  51. Lichtenstein GR, Travis S, Danese S, et al. Budesonide MMX for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis. J Crohns Colitis. 2015;9(9):738–46.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013;19(7):1404–10.

    Article  PubMed  Google Scholar 

  53. Alexakis C, Saxena S, Chhaya V, Cecil E, Curcin V, Pollok R. Do thiopurines reduce the risk of surgery in elderly onset inflammatory bowel disease? A 20-year national population-based cohort study. Inflamm Bowel Dis. 2017;23(4):672–80.

    Article  PubMed  Google Scholar 

  54. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141(5):1621–8.

    Article  CAS  PubMed  Google Scholar 

  55. Bourrier A, Carrat F, Colombel JF, et al. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther. 2016;43(2):252–61.

    Article  CAS  PubMed  Google Scholar 

  56. Abbas AM, Almukhtar RM, Loftus EV Jr, Lichtenstein GR, Khan N. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol. 2014;109(11):1781–93.

    Article  CAS  PubMed  Google Scholar 

  57. Desai A, Zator ZA, de Silva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(2):309–15.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Lobatόn T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42(4):441–51.

    Article  CAS  Google Scholar 

  59. Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Rahier JF, Magro F, Abreu C, et al. Second european evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443–68.

    Article  CAS  PubMed  Google Scholar 

  61. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.

    Article  CAS  PubMed  Google Scholar 

  62. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864–75.

    Article  CAS  PubMed  Google Scholar 

  63. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.

    Article  CAS  PubMed  Google Scholar 

  64. Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab in ulcerative colitis and Crohn’s disease patients stratified by age. Adv Ther. 2017;34(2):542–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Navaneethan U, Edminister T, Zhu X, Kommaraju K, Glover S. Vedolizumab is safe and effective in elderly patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):E17.

    Article  PubMed  Google Scholar 

  66. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36.

    Article  CAS  PubMed  Google Scholar 

  67. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4(6):760–5.

    Article  CAS  PubMed  Google Scholar 

  68. Almogy G, Sachar DB, Bodian CA, Greenstein AJ. Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. Arch Surg. 2001;136(12):1396–400.

    Article  CAS  PubMed  Google Scholar 

  69. Bewtra M, Newcomb CW, Wu Q, et al. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med. 2015;163(4):262–70.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Bollegala N, Jackson TD, Nguyen GC. Increased postoperative mortality and complications among elderly patients with inflammatory bowel diseases: an analysis of the national surgical quality improvement program cohort. Clin Gastroenterol Hepatol. 2016;14(9):1274–81.

    Article  PubMed  Google Scholar 

  71. Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15(2):182–9.

    Article  PubMed  Google Scholar 

  72. Bauer JJ, Gorfine SR, Gelernt IM, Harris MT, Kreel I. Restorative proctocolectomy in patients older than fifty years. Dis Colon Rectum. 1997;40(5):562–5.

    Article  CAS  PubMed  Google Scholar 

  73. Longo WE, Virgo KS, Bahadursingh AN, Johnson FE. Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis. Am J Surg. 2003;186(5):514–8.

    Article  PubMed  Google Scholar 

  74. McKenna NP, Mathis KL, Pemberton JH, Lightner AL. The impact of age at time of ileal pouch anal anastomosis on short and long-term outcomes in adults. Inflamm Bowel Dis. 2018;24(8):1857–65.

    Article  PubMed  Google Scholar 

  75. Delaney CP, Fazio VW, Remzi FH, et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg. 2003;238(2):221–8.

    PubMed  PubMed Central  Google Scholar 

  76. Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134(3):680–7.

    Article  PubMed  Google Scholar 

  77. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Shaukat A, Virnig DJ, Salfiti NI, Howard DH, Sitaraman SV, Liff JM. Is inflammatory bowel disease an important risk factor among older persons with colorectal cancer in the united states? A population-based case-control study. Dig Dis Sci. 2011;56(8):2378–83.

    Article  CAS  PubMed  Google Scholar 

  79. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18):1228–33.

    Article  CAS  PubMed  Google Scholar 

  80. Cheddani H, Dauchet L, Fumery M, et al. Cancer in elderly onset inflammatory bowel disease: A population-based study. Am J Gastroenterol. 2016;111(10):1428–36.

    Article  PubMed  Google Scholar 

  81. Baars JE, Kuipers EJ, van Haastert M, Nicolai JJ, Poen AC, van der Woude CJ. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol. 2012;47(12):1308–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Karvellas CJ, Fedorak RN, Hanson J, Wong CK. Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age. Can J Gastroenterol. 2007;21(7):443–6.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Bielawska B, Day AG, Lieberman DA, Hookey LC. Risk factors for early colonoscopic perforation include non-gastroenterologist endoscopists: a multivariable analysis. Clin Gastroenterol Hepatol. 2014;12(1):85–92.

    Article  PubMed  Google Scholar 

  84. Taleban S, Toosizadeh N, Junna S, et al. Frailty assessment predicts acute outcomes in patients undergoing screening colonoscopy. Dig Dis Sci. 2018. https://doi.org/10.1007/s10620-018-5129-x.

    Article  PubMed  Google Scholar 

  85. Shrestha MP, Ruel J, Taleban S. Healthcare maintenance in elderly patients with inflammatory bowel disease. Ann Gastroenterol. 2017;30(3):273–86.

    PubMed  PubMed Central  Google Scholar 

  86. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Recommended immunization schedule for adults aged 19 years or older, united states, 2018. https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf. Updated 2018. Accessed 31 Jul 2018.

  88. Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(10):1460–6.

    Article  CAS  PubMed  Google Scholar 

  89. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124(3):795–841.

    Article  PubMed  Google Scholar 

  90. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000;133(10):795–9.

    Article  CAS  PubMed  Google Scholar 

  91. Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. Fracture-associated hospitalizations in patients with inflammatory bowel disease. Dig Dis Sci. 2011;56(1):176–82.

    Article  PubMed  Google Scholar 

  92. Bernstein CN, Hitchon CA, Walld R, et al. Increased burden of psychiatric disorders in inflammatory bowel disease. Inflamm Bowel Dis. 2018. https://doi.org/10.1093/ibd/izy235.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7(1):1–33.

    Article  PubMed  Google Scholar 

  94. Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57(9):2408–15.

    Article  PubMed  Google Scholar 

  95. Nguyen GC, Munsell M, Harris ML. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis. 2008;14(8):1105–11.

    Article  PubMed  Google Scholar 

  96. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(9):2272–80.

    Article  PubMed  Google Scholar 

  97. Papa A, Papa V, Marzo M, et al. Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. Inflamm Bowel Dis. 2015;21(5):1204–13.

    Article  PubMed  Google Scholar 

  98. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462–71.

    Article  PubMed  Google Scholar 

  99. Mokbel M, Carbonnel F, Beaugerie L, Gendre JP, Cosnes J. Effect of smoking on the long-term course of ulcerative colitis. Gastroenterol Clin Biol. 1998;22(11):858–62.

    CAS  PubMed  Google Scholar 

  100. Lunney PC, Kariyawasam VC, Wang RR, et al. Smoking prevalence and its influence on disease course and surgery in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2015;42(1):61–70.

    Article  CAS  PubMed  Google Scholar 

  101. Lakatos PL, Vegh Z, Lovasz BD, et al. Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis. 2013;19(5):1010–7.

    Article  PubMed  Google Scholar 

  102. Garud S, Peppercorn MA. Ulcerative colitis: current treatment strategies and future prospects. Therap Adv Gastroenterol. 2009;2(2):99–108.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sasha Taleban.

Ethics declarations

Conflicts of interest

M.P. Shrestha declares no conflicts of interest. S. Taleban has served on the Advisory Board for Janssen.

Funding

No sources of funding were used to support the writing of this review.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shrestha, M.P., Taleban, S. Management of Ulcerative Colitis in the Elderly. Drugs Aging 36, 13–27 (2019). https://doi.org/10.1007/s40266-018-0611-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-018-0611-x